Shares of CELYAD SA/ADR (NASDAQ:CYAD) have been assigned a consensus rating of “Buy” from the six research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $46.00.
A number of brokerages have weighed in on CYAD. Zacks Investment Research cut CELYAD SA/ADR from a “hold” rating to a “sell” rating in a research note on Monday, August 27th. William Blair began coverage on CELYAD SA/ADR in a research note on Tuesday, October 30th. They issued an “outperform” rating for the company.
Hedge funds and other institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN lifted its stake in CELYAD SA/ADR by 1,109.0% in the third quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock valued at $160,000 after buying an additional 5,545 shares during the last quarter. Jane Street Group LLC raised its stake in shares of CELYAD SA/ADR by 168.9% during the first quarter. Jane Street Group LLC now owns 16,816 shares of the company’s stock worth $586,000 after purchasing an additional 10,562 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of CELYAD SA/ADR during the second quarter worth approximately $582,000. Stanley Laman Group Ltd. purchased a new stake in shares of CELYAD SA/ADR during the second quarter worth approximately $1,145,000. Finally, Victory Capital Management Inc. raised its stake in shares of CELYAD SA/ADR by 41.9% during the second quarter. Victory Capital Management Inc. now owns 604,002 shares of the company’s stock worth $18,717,000 after purchasing an additional 178,380 shares during the last quarter. Institutional investors own 7.01% of the company’s stock.
NASDAQ CYAD traded down $0.20 on Tuesday, reaching $27.97. The stock had a trading volume of 2,014 shares, compared to its average volume of 7,842. CELYAD SA/ADR has a 12-month low of $22.17 and a 12-month high of $57.59. The stock has a market cap of $277.41 million, a P/E ratio of -7.90 and a beta of 1.34.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Featured Article: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.